Edap Tms Sa (EDAP)

$4.62

-0.35

(-7.04%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $4.52
    $4.97
    $4.62
    downward going graph

    2.16%

    Downside

    Day's Volatility :9.05%

    Upside

    7.04%

    downward going graph
  • $3.60
    $9.45
    $4.62
    downward going graph

    22.08%

    Downside

    52 Weeks Volatility :61.9%

    Upside

    51.11%

    downward going graph

Returns

PeriodEdap Tms SaIndex (Russel 2000)
3 Months
-29.9%
0.0%
6 Months
-20.1%
0.0%
1 Year
-44.72%
0.0%
3 Years
-16.47%
-19.9%

Highlights

Market Capitalization
189.2M
Book Value
$1.43
Earnings Per Share (EPS)
-0.53
PEG Ratio
90.47
Wall Street Target Price
12.45
Profit Margin
-30.12%
Operating Margin TTM
-32.31%
Return On Assets TTM
-9.66%
Return On Equity TTM
-30.4%
Revenue TTM
60.5M
Revenue Per Share TTM
1.64
Quarterly Revenue Growth YOY
0.8%
Gross Profit TTM
24.2M
EBITDA
-12.7M
Diluted Eps TTM
-0.53
Quarterly Earnings Growth YOY
-0.62
EPS Estimate Current Year
-0.53
EPS Estimate Next Year
-0.39
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Edap Tms Sa(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 169.48%

Current $4.62
Target $12.45

Company Financials

FY18Y/Y Change
Revenue
44.8M
↑ 9.61%
Net Income
-386.7K
↓ 50.37%
Net Profit Margin
-0.86%
↑ 1.05%
FY19Y/Y Change
Revenue
50.3M
↑ 14.62%
Net Income
1.7M
↓ 547.34%
Net Profit Margin
3.37%
↑ 4.23%
FY20Y/Y Change
Revenue
51.2M
↓ 7.23%
Net Income
-2.1M
↓ 212.7%
Net Profit Margin
-4.09%
↓ 7.46%
FY21Y/Y Change
Revenue
49.9M
↑ 5.77%
Net Income
792.8K
↓ 141.08%
Net Profit Margin
1.59%
↑ 5.68%
FY22Y/Y Change
Revenue
59.0M
↑ 25.06%
Net Income
-3.1M
↓ 519.0%
Net Profit Margin
-5.32%
↓ 6.91%
FY23Y/Y Change
Revenue
59.2M
↑ 7.4%
Net Income
-20.7M
↑ 607.26%
Net Profit Margin
-35.05%
↓ 29.73%
Q4 FY22Q/Q Change
Revenue
15.8M
↑ 20.84%
Net Income
-8.0M
↓ 57723.08%
Net Profit Margin
-50.63%
↓ 50.74%
Q1 FY23Q/Q Change
Revenue
17.1M
↑ 6.24%
Net Income
-5.6M
↓ 31.5%
Net Profit Margin
-32.64%
↑ 17.99%
Q2 FY23Q/Q Change
Revenue
15.6M
↓ 9.16%
Net Income
-5.1M
↓ 8.44%
Net Profit Margin
-32.9%
↓ 0.26%
Q3 FY23Q/Q Change
Revenue
11.7M
↓ 17.8%
Net Income
-3.9M
↓ 16.01%
Net Profit Margin
-33.62%
↓ 0.72%
Q4 FY23Q/Q Change
Revenue
19.1M
↑ 62.82%
Net Income
-4.9M
↑ 24.52%
Net Profit Margin
-25.71%
↑ 7.91%
Q1 FY24Q/Q Change
Revenue
16.2M
↓ 21.53%
Net Income
-4.9M
↓ 6.94%
Net Profit Margin
-30.49%
↓ 4.78%
FY18Y/Y Change
Total Assets
55.8M
↑ 3.93%
Total Liabilities
27.2M
↑ 9.37%
FY19Y/Y Change
Total Assets
59.4M
↑ 8.88%
Total Liabilities
28.8M
↑ 8.13%
FY20Y/Y Change
Total Assets
67.9M
↑ 4.0%
Total Liabilities
35.6M
↑ 12.58%
FY21Y/Y Change
Total Assets
87.5M
↑ 39.92%
Total Liabilities
30.8M
↓ 6.13%
FY22Y/Y Change
Total Assets
108.3M
↑ 30.94%
Total Liabilities
31.6M
↑ 8.53%
FY23Y/Y Change
Total Assets
91.6M
↓ 9.39%
Total Liabilities
34.7M
↑ 17.51%
Q4 FY22Q/Q Change
Total Assets
107.9M
↓ 3.85%
Total Liabilities
36.2M
↑ 10.65%
Q1 FY23Q/Q Change
Total Assets
110.3M
↑ 0.35%
Total Liabilities
32.2M
↓ 12.78%
Q2 FY23Q/Q Change
Total Assets
104.0M
↓ 5.73%
Total Liabilities
35.0M
↑ 8.89%
Q3 FY23Q/Q Change
Total Assets
93.3M
↓ 2.16%
Total Liabilities
33.2M
↑ 3.32%
Q4 FY23Q/Q Change
Total Assets
91.6M
↓ 1.76%
Total Liabilities
34.7M
↑ 4.44%
Q1 FY24Q/Q Change
Total Assets
96.3M
↓ 2.69%
Total Liabilities
39.0M
↑ 4.24%
FY18Y/Y Change
Operating Cash Flow
200.2K
↓ 105.72%
Investing Cash Flow
-1.8M
↓ 22.79%
Financing Cash Flow
1.3M
↓ 58.97%
FY19Y/Y Change
Operating Cash Flow
4.3M
↑ 2071.43%
Investing Cash Flow
-1.7M
↓ 2.36%
Financing Cash Flow
-743.8K
↓ 156.37%
FY20Y/Y Change
Operating Cash Flow
2.4M
↓ 47.97%
Investing Cash Flow
-2.5M
↑ 31.27%
Financing Cash Flow
3.9M
↓ 582.08%
FY21Y/Y Change
Operating Cash Flow
5.0M
↑ 124.84%
Investing Cash Flow
-1.9M
↓ 18.55%
Financing Cash Flow
23.0M
↑ 533.11%
FY22Y/Y Change
Operating Cash Flow
-3.2M
↓ 168.03%
Investing Cash Flow
-2.5M
↑ 45.18%
Financing Cash Flow
23.3M
↑ 7.28%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.1M
↓ 380.11%
Investing Cash Flow
18.6M
↓ 193.61%
Financing Cash Flow
366.4K
↓ 98.4%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.2M
↑ 0.0%
Investing Cash Flow
-1.2M
↓ 106.53%
Financing Cash Flow
373.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.4M
↓ 11.27%
Investing Cash Flow
-1.2M
↑ 0.0%
Financing Cash Flow
24.0K
↓ 93.57%

Technicals Summary

Sell

Neutral

Buy

Edap Tms Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Edap Tms Sa
Edap Tms Sa
-6.75%
-20.1%
-44.72%
-16.47%
85.45%
Cardinal Health, Inc.
Cardinal Health, Inc.
-9.04%
-8.72%
2.55%
61.18%
114.91%
Cencora Inc
Cencora Inc
-6.12%
3.15%
25.61%
62.7%
94.63%
Mckesson Corporation
Mckesson Corporation
-4.08%
20.11%
41.1%
187.72%
322.13%
Henry Schein, Inc.
Henry Schein, Inc.
5.47%
-4.38%
-10.65%
-8.29%
5.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Edap Tms Sa
Edap Tms Sa
NA
NA
90.47
-0.53
-0.3
-0.1
NA
1.43
Cardinal Health, Inc.
Cardinal Health, Inc.
42.05
42.05
0.31
7.36
0.0
0.03
0.02
-13.38
Cencora Inc
Cencora Inc
23.39
23.39
1.58
11.93
2.34
0.03
0.01
3.39
Mckesson Corporation
Mckesson Corporation
25.91
25.91
4.96
27.59
0.0
0.04
0.0
-15.16
Henry Schein, Inc.
Henry Schein, Inc.
23.68
23.68
1.65
5.07
0.08
0.04
NA
28.02
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Edap Tms Sa
Edap Tms Sa
Buy
$189.2M
85.45%
NA
-30.12%
Cardinal Health, Inc.
Cardinal Health, Inc.
Hold
$23.1B
114.91%
42.05
0.25%
Cencora Inc
Cencora Inc
Buy
$38.5B
94.63%
23.39
0.66%
Mckesson Corporation
Mckesson Corporation
Buy
$75.2B
322.13%
25.91
0.97%
Henry Schein, Inc.
Henry Schein, Inc.
Hold
$9.0B
5.11%
23.68
3.12%

Insights on Edap Tms Sa

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 19.10M → 14.99M (in $), with an average decrease of 21.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.91M → -4.57M (in $), with an average increase of 7.5% per quarter

  • Vs MCK

    In the last 1 year, Mckesson Corporation has given 40.7% return, outperforming this stock by 84.1%

  • Vs MCK

    In the last 3 years, Mckesson Corporation has given 187.7% return, outperforming this stock by 204.2%

Institutional Holdings

  • Soleus Capital Management, L.P.

    19.48%
  • Morgan Stanley - Brokerage Accounts

    9.09%
  • Rock Springs Capital Management LP

    3.98%
  • Archon Capital Management LLC

    3.26%
  • Federated Hermes Inc

    2.18%
  • Bruce & Co Inc

    1.49%

Company Information

global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke

Organization
Edap Tms Sa
Employees
307
CEO
Mr. Marc Oczachowski
Industry
Health Technology

FAQs